Muscle Atrophy in Patients With Chronic Obstructive Pulmonary DIsease : Substudy With Patients Who Experienced an Acute Exacerbation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Obstructive Pulmonary Disease
- Sponsor
- Laval University
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Increased levels of ubiquitin proteasome pathway proteins in patients experiencing an acute exacerbation of COPD
- Last Updated
- 9 years ago
Overview
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Its prevalence is in progression and COPD is expected to become the fourth leading cause of death by 2030. COPD is characterized by periods of stability interspersed with acute infectious/inflammatory flare-ups, also called acute exacerbations, during which patients deteriorate, sometimes to the point of requiring immediate medical assistance. Although most patients eventually recover, repeated episodes of exacerbations may accelerate COPD progression. Exacerbations may further compromise the integrity of limb muscles by promoting further loss in muscle mass and strength.
The overall objective of this substudy is to elucidate how an acute COPD exacerbation may affect limb muscles.
Detailed Description
Focusing our attention during exacerbations, a period of aggravated systemic inflammation, should be more rewarding in terms of understanding the link between inflammation burst and muscle disease in COPD. We have recently acquired experimental data supporting a role for the ubiquitin proteasome pathway in the worsening of limb muscle structure and function during an acute exacerbation, providing a solid framework for this investigation. The overall objective of this proposal is to substantiate these preliminary findings and elucidate how systemic inflammation during acute COPD exacerbation may affect limb muscles. Ultimately, our research could open new therapeutic avenues to minimize the systemic consequences of an acute exacerbation.
Investigators
Annie Dubé
Professionnelle de recherche
Laval University
Eligibility Criteria
Inclusion Criteria
- •male and female
- •COPD with an FEV1 of under 60% of predicted
- •non-smoker
- •between 50 and 75 years old
- •experiencing an acute exacerbation of COPD (24-48 hours, before treatment)
Exclusion Criteria
- •all inflammatory disease (HIV, cancer, renal and cardiac deficiency)
- •hormonal dysregulation
- •inferior limb pathology
- •neuromuscular pathology
- •history of tobacco or alcool abuse
- •oxygen dependent
Outcomes
Primary Outcomes
Increased levels of ubiquitin proteasome pathway proteins in patients experiencing an acute exacerbation of COPD
Time Frame: during an acute exacerbation of COPD (first 24-48 hours, before treatment)
Our view is that targeting exacerbation is likely to unravel important mechanisms linking systemic inflammatory processes to downstream consequences on remote organs such as limb muscles. Inflammatory burst observed during exacerbation may be associated with upregulation of ubiquitin proteasome pathway (Atrogin-1, MuRF-1, Nedd4, ubiquitin C, poly-Ub), the main proteolytic pathway in this tissue, and thus with the occurrence of atrophying process.